SYSTEMIC THERAPY FOR ADVANCED KIDNEY CANCER
Authors: I.V. Timofeev
The results of recent studies will dramatically change the approaches to the treatment of metastatic renal cell carcinoma (mRCC) in the near future. Most of the changes will affect the first-line of therapy, which will lead to the emergence of a new endpoint and the goal of therapy such as a treatment-free survival. Patients on the treatment will be able to receive therapy for a long time, and developing complete responses will not require switching to the second-line. Invading new therapeutic options will increase the oncologist’s arsenal, allow to personalize therapy, plan several lines from the first visit of the patient, and increase the total duration of treatment.